GlassScriptPhysician profile
Amir N Cheema
NPI 1386707750
$9,449.83
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $210 · 2021: $1,890 · 2022: $2,101 · 2023: $2,643 · 2024: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,965.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,704.62 | 2019-2024 | Xarelto |
| Amgen INC. | $1,319.83 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $1,012.09 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $944.00 | 2021-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.27 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $536.77 | 2022-2024 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $495.41 | 2021-2024 | Farxiga, Brilinta, Wainua |
| Pfizer INC. | $427.29 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $356.46 | 2019-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $353.22 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $335.19 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $152.46 | 2021-2022 | |
| Esperion Therapeutics, INC. | $152.13 | 2024 | Nexletol |
| Novo Nordisk INC | $147.73 | 2024 | Wegovy, Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $132.55 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $121.40 | 2020 | |
| Zoll Circulation INC | $100.00 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Bayer Healthcare Pharmaceuticals INC. | $82.26 | 2021-2022 | |
| Abbott Laboratories | $71.13 | 2021-2022 | |
| Abiomed | $37.60 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $33.57 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $24.09 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $23.50 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $14.97 | 2021 | |
| Irhythm Technologies, INC. | $14.29 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.